Last €30.53 EUR
Change Today +1.78 / 6.19%
Volume 99.2K
ADOC On Other Exchanges
EN Paris
As of 11:35 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

adocia sas (ADOC) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/25/14 - €39.56
52 Week Low
11/27/13 - €5.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ADOCIA SAS (ADOC)

Related News

No related news articles were found.

adocia sas (ADOC) Related Businessweek News

No Related Businessweek News Found

adocia sas (ADOC) Details

Adocia Société Anonyme, a biotechnology company, develops medicines from therapeutic proteins. The company focuses on insulin therapy and the treatment of diabetic foot ulcer based on its BioChaperone technological platform. Its product pipeline includes BioChaperone PDGF-BB, which has completed Phase II clinical trials for the treatment of diabetic foot ulcer, as well as in pre clinical stage for the treatment of venous ulcer, and bedsores and burns; BioChaperone insulin that is in Phase II clinical trials, as well as in pre clinical stage for the treatment of diabetes; and BioChaperone for monoclonal antibodies, which is in pre clinical stage. Adocia Société Anonyme was founded in 2005 and is based in Lyon, France.

77 Employees
Last Reported Date: 07/24/14
Founded in 2005

adocia sas (ADOC) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €270.5K
Co-Founder, Deputy General Manager, Director ...
Total Annual Compensation: €160.5K
Compensation as of Fiscal Year 2012.

adocia sas (ADOC) Key Developments

Adocia Announces Revenue Results for the Third Quarter and Nine Months Ended September 30, 2014

Adocia announced revenue results for the third quarter and nine months ended September 30, 2014. For the quarter, revenues were EUR 0.1 million, were generated from research contracts on the formulation of monoclonal antibodies compared to EUR 4.7 million a year ago, principally as the result of the amortization of the upfront payment regarding the licensing contract signed with Eli Lilly. For the nine months, revenues from research and collaborative agreements was EUR 0.2 million compared to EUR 5.6 millions a year ago.

Adocia Société Anonyme Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-18-2014

Adocia Société Anonyme Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-18-2014 . Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Adocia Reports Preliminary Results from Dose Response Clinical Study of Ultra-Fast Acting Biochaperone(R) Lispro U100 in Patients with Type 1 Diabetes

Adocia announced positive preliminary results from a Phase IIa dose-response clinical trial evaluating its innovative ultra-fast formulation of insulin lispro (BioChaperone Lispro U100) tested at three doses, relative to Eli Lilly's Humalog(R) commercial insulin (insulin lispro U100). Adocia's formulation incorporates proprietary BioChaperone(R) technology which enables accelerated absorption of prandial insulins. This dose response study confirms that BioChaperone Lispro U100 more closely mimics the endogenous insulin secretion observed in healthy individuals in response to a meal than Humalog, at all tested doses. BioChaperone Lispro U100 has been tested in 73 patients (for a total of 149 injections) and was very well tolerated. Clinical results confirm the ultra-fast action of BioChaperone Lispro U100 and show a dose-response effect. In this double-blind, randomized, four-period cross-over study, the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of BioChaperone Lispro at three doses were compared to those of Humalog at a single dose. 37 patients with type 1 diabetes received three increasing doses of BioChaperone Lispro (0.1 U/kg, 0.2 U/kg and 0.4 U/kg) and one dose of Humalog (0.2 U/kg) under automated euglycemic clamp conditions (ClampArt(R), target blood glucose (BG) 100 mg/dL, clamp duration 12 hours post-dosing). All BioChaperone Lispro dosages were well tolerated and did not induce any local reaction, while Humalog was associated to an injection site erythema in one patient. In pharmacokinetics, BioChaperone Lispro showed a significantly faster rate of insulin lispro absorption than Humalog with an increase in the early insulin exposure of 136% at the same dose (AUC(lispro_0-30min) 25 +/- 10 vs. 12 +/- 7 h*mU/L; p<0.001). The time to peak insulin lispro concentration was significantly reduced (median T(max) 40 vs. 60 min; p=0.001). BioChaperone Lispro was also cleared from the blood significantly earlier than Humalog, reflected in the time to half-maximum insulin levels after T(max) (late T(50% max) = 132 +/- 41 vs. 163 +/- 49 min, p<0.001). The acceleration of insulin lispro absorption with BioChaperone translated into a significant acceleration of its metabolic effect. The early metabolic effect was increased by more than 70% relative to Humalog during the first hour after administration (AUC(GIR_0-1h) = 207 +/- 87 vs. 123 +/- 58 mg/kg; p<0.0001). In a comparable clinical setting, BioChaperone Lispro had already shown superior PK/PD profiles vs. Humalog. The reproducibility of this second clinical study confirms the robustness of the product performance. The primary objective of this study was to investigate the dose-exposure and the dose-response relationships of BioChaperone Lispro at 0.1, 0.2 and 0.4 U/kg. A dose proportionality relationship was demonstrated for the total insulin exposure and the maximum insulin lispro concentration (AUC(0-last) = 112, 213 and 452 h*mU/L and C(max) = 55, 100 and 191 mU/L for 0.1, 0.2 and 0.4 U/kg respectively). A linear dose response relationship was demonstrated for the total metabolic effect and the maximum glucose infusion rate (AUC(GIR0-last) = 726, 1357 and 2422 mg/kg and GIR(max) = 4.8, 7.4 and 10.2 mg/kg/min for 0.1, 0.2 and 0.4 U/kg respectively). The ultra-fast absorption of insulin lispro for all doses of BioChaperone Lispro is confirmed by constant time-related parameters, such as time to early maximal observed insulin lispro concentration (early T(50% max) = 15+/-5, 15+/-5 and 15+/-5 min at 0.1, 0.2 and 0.4 U/kg respectively).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADOC:FP €30.53 EUR +1.78

ADOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADOC.
View Industry Companies

Industry Analysis


Industry Average

Valuation ADOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.5x
Price/Book 11.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADOCIA SAS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at